Skip to content
CFPS Research Archives

Mazdutide

Human clinical Weight Loss & Metabolism 2 sources

Mazdutide is an investigational dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. Clinical research indicates it significantly reduces body weight and improves metabolic parameters in individuals with obesity or type 2 diabetes by suppressing appetite and increasing energy expenditure.

01Dosing reference

Amount
3 mg to 9 mg
Frequency
Once weekly
Cycle
Continuous weekly administration with gradual dose titration
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

GLP-1 Receptor Activation

Binds to GLP-1 receptors in the pancreas and brain to enhance glucose-dependent insulin secretion and suppress appetite.

02

Glucagon Receptor Activation

Binds to glucagon receptors in the liver and adipose tissue, promoting lipid metabolism and increasing energy expenditure.

03

Synergistic Metabolic Effect

The combined activation leads to greater weight loss and reduction in liver fat compared to GLP-1 agonism alone.

03Human evidence

Significant weight loss of up to 15-19% over 48 weeks in overweight and obese adults.

Phase 2 and 3 clinical trials in Chinese populations, demonstrating dose-dependent efficacy.

Improvements in glycemic control, lipid profiles, and reduction in liver fat content.

Clinical trials involving patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).

04Preclinical evidence

Robust weight loss and reduced food intake in animal models.

Studies in diet-induced obese mice and non-human primates.

Increased energy expenditure and improved hepatic steatosis.

Preclinical models evaluating the specific contribution of the glucagon receptor component.

05What is known vs. unknown

Reasonably established
  • Acts as a dual GLP-1 and Glucagon receptor agonist.
  • Demonstrates substantial weight loss efficacy in late-stage clinical trials.
  • Improves glycemic control and reduces liver fat content.
  • Administered via once-weekly subcutaneous injection.
Unknowns & limits
  • Long-term cardiovascular safety and outcomes are still being evaluated in ongoing trials.
  • Optimal dosing strategies to balance maximum efficacy with gastrointestinal tolerability across diverse global populations require further study.

06Safety & regulatory context

Regulatory statusMazdutide is currently in late-stage (Phase 3) clinical trials and is not yet FDA-approved. Its safety profile is generally consistent with other incretin-based therapies, with the most common side effects being gastrointestinal issues such as nausea, vomiting, and diarrhea. Due to its glucagon receptor agonism, it may also cause mild increases in heart rate. It is being developed primarily for obesity and type 2 diabetes.

07Compared with Tirzepatide

Mazdutide vs. Tirzepatide
Key difference
Mazdutide targets GLP-1 and Glucagon receptors to increase energy expenditure, whereas Tirzepatide targets GLP-1 and GIP receptors to enhance the incretin effect.
When researchers discuss each
Researchers discuss Mazdutide when exploring the benefits of adding glucagon agonism for enhanced fat burning and liver fat reduction, while Tirzepatide is discussed for its potent glycemic control and weight loss via GIP.

08Glossary

GLP-1 (Glucagon-like peptide-1)
A hormone that stimulates insulin secretion, delays gastric emptying, and reduces appetite.
Glucagon
A hormone that typically raises blood glucose levels but also increases energy expenditure and fat breakdown.
Dual Agonist
A single molecule designed to bind to and activate two different cellular receptors simultaneously.

09Knowledge check

Q1Which two receptors does Mazdutide target?
Q2What is a unique physiological effect of the glucagon receptor activation in Mazdutide?
Q3Which of the following is a documented limitation of the current clinical research on Mazdutide?
Q4In direct research comparisons with Tirzepatide, for what feature do researchers particularly discuss Mazdutide?
Q5Which statement about Mazdutide’s regulatory and safety status is supported by the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism
Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism
Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism
Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.